Informace o projektu
European Proteomics Infrastructure Consortium providing Access
(EPIC-XS)
- Kód projektu
- 823839
- Období řešení
- 1/2019 - 6/2023
- Investor / Programový rámec / typ projektu
-
Evropská unie
- Horizon 2020
- RI Research Infrastructures (Excellent Science)
- Fakulta / Pracoviště MU
- Středoevropský technologický institut
- Spolupracující organizace
-
Mikrobiologický ústav AV ČR, v. v. i.
- Odpovědná osoba RNDr. Petr Novák, PhD.
Kobenhavns Universitet
Tartu Ülikool
University of Cambridge
Universität Tübingen
Universiteit Utrecht
- Odpovědná osoba Prof. Dr. Albert Heck
Universitetet i Bergen
Fundacio Centro Nacional de Investigationes Oncologicas Carlos III C
Istituto Europeo di Oncologia
Institut Pasteur
Royal Institute of Technology (KTH)
Centre for Genomic Regulation
Centre for Research and Technology Hellas
VIB
EMBL ¨(EUROPEAN MOLECULAR BIOLOGY LABORATORY)
Forschungsinstitut für Molekulare Pathologie (IMP)
In life sciences research, proteomics technologies promise to be even more revolutionary than genomics for understanding the molecular mechanisms of complex biological systems and their (mal-)functions in health and disease. As a result, there is a strongly growing need for the integration of proteomic technologies into world-class life sciences research programs in medicine, agriculture, food, biotechnology, and materials.
The European Proteomics Infrastructure Consortium providing Access (EPIC-XS) brings together a consortium of world-leading, highly innovative European proteomics facilities with the shared goal of supporting excellent life sciences research in Europe. This will be achieved by providing access to cutting-edge proteomics facilities, and by developing and implementing novel mass spectrometry based proteomics and bioinformatics approaches to shape the future life sciences research in Europe.
The Transnational Access in EPIC-XS consists of around 2400 days of access to state-of-the-art proteomics facilities, corresponding to around 150 user projects, which will be evaluated by an independent review panel to ensure excellence, and to match users with the best facility for their challenging research questions.
The cutting-edge Joint Research Activities in EPIC-XS are built on the extremely strong innovation track record of the consortium members, and will address bottlenecks in, and develop novel approaches for, future-oriented efforts in computational and structural proteomics, analysis of higher-order proteome organization, multi-omics integration, and translational/clinical proteomics and personalized/precision medicine.
EPIC-XS will provide users with unrivalled access to world-leading facilities and expertise, while simultaneously extending Europe’s leading international role in the. EPIC-XS meets the widespread current demands for user access, addresses present bottlenecks in the field and will open up entirely new perspectives in proteomics.
Publikace
Počet publikací: 2
2023
-
New findings on the action of hypericin in hypoxic cancer cells with a focus on the modulation of side population cells
Biomedicine and Pharmacotherapy, rok: 2023, ročník: 163, vydání: July, DOI
2022
-
PDBe-KB: collaboratively defining the biological context of structural data
Nucleic acids research, rok: 2022, ročník: 50, vydání: D1, DOI